Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 280

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 280
---
 adjustments that may be identified when audit work is performed on the Company’s year-end financial
statements, which could result in significant differences from this unaudited financial information.

<div align='center'>156

DIAMIR’S BUSINESS</div>

DiamiR conducts all of its
operations through its wholly-owned operating subsidiary, DiamiR, LLC (“DiamiR, LLC”), which is a molecular diagnostic company
initially focused on development and commercialization of innovative blood-based tests for minimally invasive risk assessment and monitoring
of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases
(NDs). The proprietary technology developed at DiamiR is based on quantitative analysis of circulating organ-enriched microRNAs (miRNAs)
in plasma, a class of molecules distinct from proteins; thus, this approach tests a separate biological pathway than traditional blood
protein markers interrogate. The technology also can be applied to disease areas beyond NDs, including, a rare neurological and developmental
disorder Rett syndrome, cancer, and inflammatory disorders, where DiamiR’s work is at an early stage.

DiamiR’s business objectives
include the development of lab-developed tests (LDTs) under Clinical Laboratory Improvement Amendments (CLIA) and FDA oversight guidelines
primarily based on the identified miRNA signatures, and potentially the development of blood protein biomarkers for risk stratification
of cognitively unimpaired individuals vs MCI vs AD patients. DiamiR believes the tests will be used to facilitate enrollment of better-defined
patient groups into clinical trials that are less heterogeneous than current practice affords, as well as for disease and treatment monitoring
and screening. DiamiR believes clinical tests for risk stratification are a valuable tool for personalized medicine, allowing healthcare
providers to allocate resources efficiently and deliver targeted interventions to those who are most likely to benefit.

The first test in the DiamiR’s
pipeline, CogniMIR, will be used to detect and determine risk of MCI, a heterogeneous condition characteristic of many
NDs. Initially, CogniMIR could be used by clinicians and researchers to screen patients for clinical studies aiming to
prevent or to intervene early in the development of neurodegeneration.

DiamiR aims to follow the development
of CogniMIR with the development and commercialization of tests for early, specific identification and monitoring of AD,
PD, other NDs, R